Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEV 239
- Development stage
- Phase 4
- Lead developer
- Xiamen Innovax Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
HEV 239 is a recombinant protein-subunit vaccine developed to prevent infection by the hepatitis E virus (HEV). It contains virus-like particles derived from a specific fragment of the HEV genotype 1 ORF2 capsid protein (amino acids 368–606), produced using a recombinant Escherichia coli expression system. The vaccine is adjuvanted with aluminum hydroxide and administered intramuscularly in a three-dose schedule at months 0, 1, and 6. Clinical trials have demonstrated high immunogenicity and efficacy against symptomatic HEV infection—particularly for genotypes prevalent in Asia and Africa—with seroconversion rates near or at 100% after full vaccination. The primary indication is prevention of acute hepatitis E in adults aged ≥16 years; it has been licensed for use in China since 2011 and recommended by WHO for outbreak settings. Safety data show that adverse events are generally mild, mostly limited to local injection site reactions[1][2][3][4][5].
- Brand names
- Hecolin
- Other names
- hepatitis E vaccine (HEV 239)recombinant hepatitis E vaccineHecolin vaccine
02
Targets
HEV ORF2 (Hepatitis E virus capsid protein)
Beyond the preview
Go deeper on HEV 239.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEV 239.